

Clinical trials of CEPT inhibition for cardiovascular prevention in all type of patients

TrialResults-center www.trialresultscenter.org

1 CETP inhibitor

Trial	Treatments	Patients	Trials design and methods
dalcetrapib vs			
NCT01516541 <i>ongoing</i> [NCT01516541] n=2220 follow-up:	dalcetrapib 600 mg orally daily versus placebo	patients with stable coronary heart disease (CHD), with CHD risk equivalents or at elevated risk for cardiovascular disease	
NCT01059682 <i>ongoing</i> [NCT01059682] n=936 follow-up:	dalcetrapib 600 mg orally once a day versus placebo	subjects undergoing coronary angiography who have coronary artery disease	
anacetrapib vs placebo			
REVEAL HPS-3 TIMI-55 , 2017 [NCT01252953] n=30624 follow-up: median 4 years	anacetrapib 100mg daily versus placebo	high risk patients already taking statins	Parallel groups double-blind
REALIZE , 2015 [NCT01524289] n=204/102 follow-up: 52 weeks	oral anacetrapib 100 mg for 52 weeks versus placebo	patients aged 18-80 years with a genotype-confirmed or clinical diagnosis of heterozygous familial hypercholesterolaemia, on optimum lipid-lowering treatment for at least 6 weeks, and with an LDL-C concentration of 259 mmol/L or higher without cardiovascular disease or 181 mmol/L or higher with cardiovascular disease	Parallel groups double-blind
DEFINE , 2010 [NCT00685776] n=811/812 follow-up:	anacetrapib 100mg fr 18 months versus placebo	patients with coronary heart disease or at high risk for coronary heart disease	Parallel groups double-blind 20 countries
dalcetrapib vs placebo			
dal-VESSEL , 2011 n=NA follow-up: 12 weeks	dalcetrapib 600 mg daily versus placebo	men and women with coronary heart disease or coronary heart disease risk equivalents with HDL-cholesterol levels <50 mg/dL	Parallel groups double-blind
dal-OUTCOMES , 2012 [NCT00658515] n=7938/7933 follow-up: 31 montsh (median)	dalcetrapib 600 mg daily beginning 4 to 12 weeks after an index ACS event versus placebo	patients with recent acute coronary syndrome	Parallel groups double-blind 27 countries

continued...

Trial	Treatments	Patients	Trials design and methods
evacetrapib vs placebo			
ACCELERATE , 2017 [NCT01687998] n=6038/6054 follow-up:	evacetrapib at adose of 130 mg versus placebo	Patients at a High-Risk for Vascular Outcomes who had at least one of the following conditions: an acutecoronary syndrome within the previous 30 to 365 days, cerebrovascular atheroscleroticdisease, peripheral vascular arterial disease, or diabetes mellitus with coronaryartery disease	Parallel groups double-blind 37 countries
torcetrapib vs placebo			
RADIANCE 1 , 2007 [NCT00136981] n=450/454 follow-up: 24 months	atorvastatin combined with 60 mg of torcetrapib versus atorvastatin monotherapy	patients with heterozygous familial hypercholesterolemia	Parallel groups open
ILLUMINATE , 2007 [NCT00134264] n=7533/7534 follow-up: 1.52y	torcetrapib 60mg daily plus atorvastatin (at a dose established during the runinperiod) versus atorvastatin alone	patients at highcardiovascular risk	Parallel groups double blind 7 countries
RADIANCE 2 , 2007 n=377/375 follow-up: 24 months	torcetrapib 60mg daily (on top of atorvastatin attitrated dose) versus placebo +atorvastatin attitrated dose	patients with mixed dyslipidaemia	Parallel groups double blind North America and Europe
ILLUSTRATE , 2007 [NCT00134173] n=591/597 follow-up: 24 months	atorvastatin plus 60 mg of torcetrapib daily versus atorvastatin monotherapy	patients with coronary disease	Parallel groups open North America and Europe

References

NCT01516541, :

NCT01059682, :

REVEAL HPS-3 TIMI-55, 2017:

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. N Engl J Med 2017;; [28847206]

REALIZE, 2015:

Kastelein JJ, Besseling J, Shah S, Bergeron J, Langslet G, Hovingh GK, Al-Saady N, Koeijvoets M, Hunter J, Johnson-Levonas AO, Fable J, Sapre A, Mitchel Y Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet 2015 Mar 2;; [25743173] 10.1016/S0140-6736(14)62115-2

DEFINE, 2010:

Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, Stepanavage M, Liu SX, Gibbons P, Ashraf TB, Zafarino J, Mitchel Y, Barter P Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease. N Engl J Med 2010 Nov 17;; [21082868] 10.1056/NEJMoa1009744

dal-VESSEL, 2011:

dal-OUTCOMES, 2012:

Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Shah PK, Tardif JC, Chaitman BR, Duttlinger-Maddux R, Mathieson J Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J 2009 Dec;158:896-901.e3 [19958854]

Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome. *N Engl J Med* 2012 Nov 5;: [23126252] [10.1056/NEJMoa1206797](https://doi.org/10.1056/NEJMoa1206797)

ACCELERATE, 2017:

Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, Gibson CM, Granger C, Menon V, Montalescot G, Rader D, Tall AR, McErlean E, Wolski K, Ruotolo G, Vangerow B, Weerakkody G, Goodman SG, Conde D, McGuire DK, Nicolau JC, Leiva-Pons JL, Pe Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. *N Engl J Med* 2017;376:1933-1942 [28514624]

RADIANCE 1, 2007:

Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, Revkin JH, Grobbee DE, Riley WA, Shear CL, Duggan WT, Bots ML Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. *N Engl J Med* 2007 Apr 19;356:1620-30 [17387131] [10.1056/NEJMoa071359](https://doi.org/10.1056/NEJMoa071359)

ILLUMINATE, 2007:

Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B Effects of torcetrapib in patients at high risk for coronary events. *N Engl J Med* 2007 Nov 22;357:2109-22 [17984165] [10.1056/NEJMoa0706628](https://doi.org/10.1056/NEJMoa0706628)

RADIANCE 2, 2007:

Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, Shear CL, Duggan WT, Vicari RM, Grobbee DE, Kastelein JJ Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. *Lancet* 2007;370:153-60 [17630038]

ILLUSTRATE, 2007:

Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM Effect of torcetrapib on the progression of coronary atherosclerosis. *N Engl J Med* 2007;356:1304-16 [17387129]

2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.